Caldera Therapeutics

United States
Primghar, Iowa, United States, 02139

Company profile

Caldera Therapeutics company profile

Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits. Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2025-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$112.5M
Last funding
Series A / $37.5M / 2026-01-14
Last equity funding
Series A / $37.5M
Investors
6
Lead investors
1
Articles
10

Founders and investors

Lead investors

Omega Funds

Investors

Atlas VentureJanus Henderson InvestorsLilly Asia VenturesOmega FundsWellington Management